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O B J E C T I V E S The aim of this study was to evaluate the independent prognostic signiﬁcance of
ischemia change in stable coronary artery disease (CAD).
B A C KG ROUND Recent randomized trials in stable CAD have suggested that revascularization
does not improve outcomes compared with optimal medical therapy (MT). In contrast, the nuclear
substudy of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evalua-
tion) trial found that revascularization led to greater ischemia reduction and suggested that this may be
associated with improved unadjusted outcomes. Thus, the effects of MT versus revascularization on
ischemia change and its independent prognostic signiﬁcance requires further investigation.
METHOD S From the Duke Cardiovascular Disease and Nuclear Cardiology Databanks, 1,425
consecutive patients with angiographically documented CAD who underwent 2 serial myocardial
perfusion single-photon emission computed tomography scans were identiﬁed. Ischemia change was
calculated for patients undergoing MT alone, percutaneous coronary intervention, or coronary artery
bypass grafting. Patients were followed for a median of 5.8 years after the second myocardial perfusion
scan. Cox proportional hazards regression modeling was used to identify factors independently
associated with the primary outcome of death or myocardial infarction (MI). Formal risk reclassiﬁcation
analyses were conducted to assess whether the addition of ischemia change to traditional predictors
resulted in improved risk classiﬁcation for death or MI.
R E S U L T S More MT patients (15.6%) developed 5% ischemia worsening compared with those
undergoing percutaneous coronary intervention (6.2%) or coronary artery bypass grafting (6.7%) (p 
0.001). After adjustment for established predictors, 5% ischemia worsening remained a signiﬁcant
independent predictor of death or MI (hazard ratio: 1.634; p  0.0019) irrespective of treatment arm.
Inclusion of 5% ischemia worsening in this model resulted in signiﬁcant improvement in risk
classiﬁcation (net reclassiﬁcation improvement: 4.6%, p  0.0056) and model discrimination (integrated
discrimination improvement: 0.0062, p  0.0057).
CONC L U S I O N S In stable CAD, ischemia worsening is an independent predictor of death or MI,
resulting in signiﬁcantly improved risk reclassiﬁcation when added to previously known predictors. (J Am
Coll Cardiol Img 2012;5:715–24) © 2012 by the American College of Cardiology Foundation
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716ecent randomized trials have shown no im-
provement in death or myocardial infarction
(MI) with an early revascularization strategy
compared with initial optimal medical ther-
py (MT) in patients with stable coronary artery
isease (CAD) (1,2). However, the COURAGE
Clinical Outcomes Utilizing Revascularization and
ggressive Drug Evaluation) nuclear substudy
ound that revascularization more frequently re-
ulted in 5% ischemia reduction and suggested in
n unadjusted analysis that this ischemia reduction
ay be associated with improved outcomes (3).
mportantly, this association was not maintained after
djustment to treatment arm, and multivariate adjust-
ent to other known predictors was not possible, be-
ause this exploratory substudy was not powered to
xamine clinical outcomes. Thus, in patients with stable
CAD, the relative effects of MT and revascu-
larization on ischemia require further investi-
gation, and the independent prognostic signif-
icance of ischemia change is unclear.
Despite these uncertainties, in clinical prac-
tice, ischemia is 1 of the primary drivers of
decisions regarding revascularization in pa-
tients with stable CAD (4). Therefore, clarifi-
cation of these questions has significant impli-
cations for both patient management and
healthcare resource utilization.
The aims of this study were threefold:
1) to compare the change in ischemia with
MT, percutaneous coronary intervention
(PCI), or coronary artery bypass grafting
(CABG) as measured by serial myocardial
perfusion single-photon emission com-
puted tomography (MPS) scans in a large
cohort of patients with stable CAD; 2) to
valuate the independent prognostic utility of isch-
mia change; and 3) to assess whether the addition
f ischemia change to traditional predictors results
n improved risk classification for death or MI.
M E T H O D S
We conducted an observational analysis of patients
from the Duke Cardiovascular Disease and Nuclear
Radiology, Duke University Medical Center, Durham, North Carolina.
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ass
se
ion
yManuscript received November 21, 2011; revised manuscript received JanuarCardiology Databanks. The Duke Cardiovascular
Disease Databank is a prospective longitudinal
record of the details and clinical courses of53,000
cardiovascular patients in the Duke University
Health System with angiographically significant
CAD (75% stenosis of at least 1 major epicardial
coronary artery). All patients are followed at 6
months, 1 year, and annually thereafter, with re-
cording of major clinical events. The Duke Nuclear
Cardiology Databank contains the clinical details of
50,000 MPS scans performed at Duke over the
past 15 years.
Study population. We identified 1,425 consecutive
patients with angiographically documented CAD
who underwent 2 serial MPS scans between Sep-
tember 1993 and June 2009 within a 36-month
time frame (Fig. 1). All patients had CAD docu-
mented by coronary angiography within 180 days of
their MPS studies. Patients with incomplete angio-
graphic or nuclear data were excluded.
Clinical variables. Demographic and clinical charac-
teristics were recorded prospectively at the time of
coronary angiography and MPS. Prospectively col-
lected variables included age, sex, race, left ventric-
ular (LV) ejection fraction (LVEF), hypertension,
diabetes, smoking history, hyperlipidemia, New
York Heart Association functional classification, car-
diac medications, CAD severity as reflected by the
number of diseased vessels, prior MI, history of
revascularization, and a modified Charlson comorbid-
ity index (5).
Stress testing and single-photon emission computed
tomography imaging. Patients capable of exercise
nderwent treadmill stress testing with the Bruce
rotocol, unless an alternative protocol was re-
uested by the ordering physician. Patients unable
o exercise underwent pharmacological stress test-
ng. MPS scans were performed according to pre-
iously described Duke University nuclear labora-
ory protocols (6,7). In brief, single-photon
mission computed tomography images were ob-
ained with multiple-head detectors, with 30 s/pro-
ection at rest and 20 s/projection during stress. The
tudies were clinically interpreted by 3 nuclear
ardiologists in our laboratory, without attenuation
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717correction. Commercially available software (Ce-
dars Sinai QGS/QPS [Cedars-Sinai Medical Cen-
ter, Los Angeles, California] or Emory Toolbox
[Emory University, Atlanta, Georgia]) was used to
determine the gated single-photon emission com-
puted tomography LVEF.
The MPS studies were evaluated semiquantita-
tively for the severity and extent of abnormalities,
with relative perfusion recorded in each myocardial
segment (0  no defect, 1  mild defect, 2 
oderate defect, and 3  severe defect) at rest and
uring stress. The summed difference score, which
s the sum of the differences between the stress and
est perfusion scores (reversible defects), was deter-
ined for each patient. The Duke Nuclear Cardi-
logy Databank has used a 4-point severity scale
ince its inception and was initiated before the
urrent American Society of Nuclear Cardiology–
ecommended 5-point scale. We have kept the
ame system of scoring to maintain consistency
hroughout our database over time. At the time
hese data were collected, we used a 12-segment
odel. We used a previously reported algorithm for
he conversion of 12-segment perfusion scores to
7-segment scores, which is highly correlated with
xpert reading of the same studies using the 17-
egment model (8). Thus, we have a robust method
or converting 12-segment data into 17-segment
ata. In addition, we have previously shown that the
rognostic value of the converted data is nearly
dentical to the prognostic information derived
rom our 12-segment model data (8). The percent-
ge LV ischemia for each scan was calculated as:
00  summed difference score/51 (8). For each
atient, the change in LV ischemia between the 2
PS scans was calculated.
Follow-up and outcomes. Treatment group was as-
signed on an intention-to-treat basis. Patients were
included in the PCI (n 419) or CABG (n 135)
group on the basis of the first revascularization
procedure occurring within 60 days of the first MPS
scan (Fig. 1). If no revascularization occurred
within this period, they were assigned to the MT
group (n  871). Follow-up time was initiated at
the second MPS scan. The primary endpoint was a
composite of death or MI. An independent clinical
events committee reviewed and classified major
clinical events without knowledge of the clinical
data or MPS results. Follow-up was 96% complete.
Statistical analysis. Differences in baseline character-
istics were compared using t tests or chi-square
statistics. When appropriate, paired t tests were
used to compare paired data. Continuous variables ithat were not distributed normally were compared
using Wilcoxon rank sum tests for independent
groups and Wilcoxon signed rank tests for paired
data. On the basis of the nuclear substudy of
COURAGE, a threshold change in ischemia of
5% of the LV was used. The COURAGE inves-
tigators chose this value because it represented a
change that exceeded test repeatability (9).
Kaplan-Meier methods were used to evaluate
time to the primary outcome of death or MI. Cox
proportional hazards regression modeling was used
to identify factors that were independently associ-
ated with death or MI. After examining the results
of a flexible Cox model-fitting approach involving
cubic polynomial spline functions (10), the linearity
of the unadjusted relationship between each con-
tinuous variable and death or MI was assessed. The
proportionality assumption was verified using
Schoenfeld residuals. For the multivariate model,
covariates were chosen on the basis of known
clinical risk factors as well as by stepwise selection
(and backward elimination) at p  0.05 from the
list of baseline characteristics. To explore potential
modifying effects of baseline ischemia, the interac-
tion between 5% ischemia improvement or wors-
ening and ischemia on the first scan was tested in
the adjusted Cox model.
To assess the added prognostic value of 5%
1,425 Patients With Stable CAD
(   75% Stenosis In One Or More Coronary Artery)
12 Months*
< 60
PCI
n=419
MT
n=871
CABG
n=135
MPS
MPS
>
Figure 1. Study Population and Design
A total of 1,425 consecutive patients with angiographically docume
onary artery disease (CAD) who underwent 2 serial myocardial perf
single-photon emission computed tomography (MPS) scans betwee
tember 1993 and June 2009 within a median of 12 months (*) wer
included in the study. Patients were included in the percutaneous c
intervention (PCI) or coronary artery bypass grafting (CABG) group
basis of the ﬁrst revascularization procedure occurring within 60 da
ﬁrst MPS scan. MT  medical therapy. Days
nted cor-
usion
n Sep-
e
oronary
on the
ys of theschemia worsening, the final model was compared
t
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718with a model in which 5% ischemia worsening was
not included. The global chi-square statistic for both
models was calculated, and a likelihood ratio test was
performed. Model discrimination was compared by
calculating the integrated discrimination improve-
ment, which measures the improvement in the
average sensitivity and specificity of the model with
the new predictor (11). In addition, the C-statistic
for each model was derived. Formal risk reclassifi-
cation analyses were conducted by examining the
net reclassification improvement (NRI) statistics
(11). Ten-year risk for death or MI was categorized
as 0% to 20%, 20% to 40%, 40% to 60%, and
60%. Risk categories determined on the basis of
racteristics
MT
(n  871)
PCI
(n  419)
CABG
(n  135) p Value
61 (53–71) 63 (54–72) 63 (54–70) 0.302
67 67 72 0.569
28 (25–31) 29 (26–32) 28 (25–32) 0.084
61 57 64 0.273
71 74 70 0.547
70 71 66 0.481
78 78 83 0.380
dex 1 (0–1) 1 (0–1) 1 (0–2) 0.385
44 32 35 0.001
71 51 27 0.001
0.014
84 81 89
2 3 1
5 5 3
6 7 4
3 4 3
32 32 33 0.994
98 99 99 0.098
cations 74 82 71 0.002
90 94 95 0.009
58 (48–65) 58 (50–65) 58 (48–66) 0.559
0.001
41 44 9
25 29 30
34 27 61
f left ventricle) 0.001
5.8 8.4 13.1 11.6 16.4 13.4
e range) 2 (0–9) 10 (5–19) 14 (5–24)
ia (% of left 0.634
5.0 8.2 5.2 8.2 5.9 9.5
e range) 0 (0–8) 0 (0–9) 0 (0–10)
artile range), %, or mean SD. Q1 25th percentile, Q2 75th percentile; CHF
ailure symptoms.
ABG coronary artery bypass grafting; CHF congestive heart failure; LVEF
ction; MI  myocardial infarction; MT  medical therapy; PCI  percutaneousthe models with and without 5% ischemia wors-
ening were cross-tabulated to describe the number
and percent of patients who were reclassified ap-
propriately (i.e., to a lower risk group for nonevents
or to a higher risk group for events) and inappro-
priately (i.e., to a lower risk group for events or to a
higher risk group for nonevents). The NRI was
estimated as: ([number of events reclassified higher 
number of events reclassified lower]/number of
events)  ([number of nonevents reclassified lower 
number of nonevents reclassified higher]/number of
nonevents). Assessment of overall model fit was
performed using the survival-adapted Hosmer-
Lemeshow chi-square statistic (12).
All tests were 2-tailed, and statistical significance
was declared at alpha0.05. Statistical analyses was
performed using SAS version 8.2 (SAS Institute,
Inc., Cary, North Carolina). The study protocol
was reviewed and approved by the Duke University
Medical Center institutional review board.
R E S U L T S
Baseline clinical characteristics. The median patient
age was 62 years, and 68% were men, with 61%
having undergone prior revascularization. There
were histories of diabetes in 32% and of MI in 39%.
The median LVEF was 58%. The median time
between MPS scans was 12 months. The distribu-
tion of clinical characteristics in the 3 treatment
groups is shown in Table 1.
Indications for performance of second scan. Symp-
oms of chest pain or shortness of breath or fatigue
ere the main clinical indications for performance
f the second scan (Online Table 1). A few had
rrhythmias (most commonly atrial fibrillation) as
heir indication for scanning. The remainder had a
ariety of miscellaneous indications, including pre-
perative testing, abnormal electrocardiographic
ndings, and dizziness.
Pre-treatment and post-treatment ischemia. There
as significantly greater baseline ischemia in the
ABG and PCI groups compared with the MT
roup (p  0.001) (Table 1). However, there was
no significant difference in ischemia among the 3
groups after treatment (p  0.634).
There was an overall significant reduction in
ischemia in all 3 groups (Online Fig. 1). Reduction
in ischemia was significantly greater in the CABG
and PCI groups compared with the MT group
(Online Fig. 2). In addition, significantly greater
ischemia reduction occurred in the CABG groupTable 1. Baseline Cha
Age (yrs)
Men
BMI (kg/m2)
Smokers
Hypertension
Hyperlipidemia
White race
Noncardiac Charlson in
History of MI
Prior revascularization
CHF class
0*
I
II
III
IV
Diabetes
Medications
Aspirin
Lipid-lowering medi
Beta-blockers
LVEF (%)
Diseased vessels
1
2
3
Baseline ischemia (% o
Mean  SD
Median (interquartil
Post-treatment ischem
ventricle)
Mean  SD
Median (interquartil
Values are median (interqu
class 0 signiﬁes no heart f
BMI body mass index; C
left ventricular ejection fracompared with the PCI group (p  0.0218).
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719Change in ischemia in the 3 treatment groups was
not significantly different when comparing subjects
in the study from before the year 2000 with those
afterward.
Patients with improvement in ischemia. In the MT
roup, 175 patients (20.1%) had improvements in
schemia of 5%, compared with 219 (52.3%) in
he PCI group and 84 (62.2%) in the CABG group.
he proportion of patients with 5% ischemia
mprovement was significantly greater in the
ABG and PCI groups compared with the MT
roup (p  0.0001) (Online Fig. 3). Significantly
ore of the CABG population had 5% improve-
ent in ischemia compared with the PCI group
p 0.0470). The proportion of patients with5%
ischemia improvement was not significantly differ-
ent when comparing subjects in the study from
before the year 2000 with those afterward.
Patients with worsening ischemia. In the MT group,
36 patients (15.6%) had worsening ischemia of
5%, compared with 26 (6.2%) in the PCI group
nd 9 (6.7%) in the CABG group. The proportion
f patients with 5% ischemia worsening was
ignificantly greater in the MT group compared
ith the PCI and CABG groups (p  0.0053)
Fig. 2). Similar proportions of patients in the PCI
nd CABG groups had 5% ischemia worsening
p 0.8400). The proportion of patients with5%
ischemia worsening was not significantly different
when comparing subjects in the study from before
the year 2000 with those afterward.
Change in ischemia and clinical outcomes. Patients
were followed for a median of 5.8 years. There was
a significant difference in Kaplan-Meier event rates
(p  0.0001) between patients with 5% ischemia
worsening and those with5% ischemia worsening
(Fig. 3). After 5 years, the composite endpoint of
death or MI occurred in 43% of patients with 5%
ischemia worsening compared with 26% of those
with 5% ischemia worsening. There was also a
significant difference in Kaplan-Meier event rates
(p  0.0199) between patients with 5% ischemia
improvement and those with 5% ischemia im-
provement (Fig. 4). Of the 871 patients initially
assigned to the MT group (on the basis of treat-
ment within 60 days of the first MPS scan), 345
(39.6%) subsequently underwent revascularization
during follow-up.
Multivariate analysis. After adjustment for clinical
and established risk predictors, as well as treatment
arm, the association of 5% ischemia worsening
with increased risk for death or MI remained
significant (hazard ratio: 1.634; p  0.0019) l(Table 2). Age, diabetes, noncardiac Charlson in-
dex, history of MI, hypertension, white race, smok-
ing, New York Heart Association functional class,
LVEF, and number of diseased vessels also re-
mained statistically significant. Residual ischemia
on the final scan was not a significant independent
predictor when ischemia worsening was included in
this multivariate model. In addition, there was no
significant interaction between baseline ischemia (at
scan 1) and 5% ischemia worsening in our final
model (p  0.56). The model remained unchanged
when the clinical indications for scan 2 were in-
cluded as additional variables. In particular, the
clinical indications for scan 2 were not significant
predictors of events.
When comparing this full model with a model
with 5% ischemia worsening removed, the full
model was a better fit as assessed by the likelihood
ratio test (p  0.002). Assessment of model dis-
crimination also showed significant improvement
after the addition of5% ischemia worsening, with
an integrated discrimination improvement of
0.0062 (p  0.0057), despite a very small increase
in the C-statistic (from 0.7109 to 0.7149). Assess-
ment of model calibration showed that the survival-
adapted Hosmer-Lemeshow chi-square statistic
was 2.85 (p  0.42) for both models, suggesting
that neither model had a significant lack of fit.
Although 5% ischemia improvement had an
association with death or MI (hazard ratio: 0.825;
p  0.0444) in the unadjusted setting, this was no
%
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Figure 2. Percentage of Patients With Worsening Ischemia (>5%
In the MT group, 15.6% of patients had worsening ischemia of 5%
pared with 6.2% in the PCI group and 6.7% in the CABG group. Th
tion of patients with 5% ischemia worsening was signiﬁcantly gre
the MT group compared with the PCI or CABG group (p  0.0053).
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720ables (age, diabetes, history of MI, hypertension,
race, smoking, New York Heart Association func-
tional class, and noncardiac Charlson index) (haz-
ard ratio: 0.896; p 0.2584). In addition, there was
o significant interaction between baseline ischemia
at scan 1) and 5% ischemia improvement in our
nal model (p  0.21), indicating that the effect of
5% ischemia improvement on outcome was not
ignificantly different in those with greater baseline
schemia.
Risk reclassiﬁcation. Table 3 shows the cross-
abulations of the 10-year estimated risk using the
odels with and without 5% ischemia worsening.
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Figure 3. Kaplan-Meier Curve of Patients With >5% Versus <5%
There was a signiﬁcant difference in Kaplan-Meier event rates (p 
with 5% ischemia worsening. Patients were followed for a median
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Figure 4. Kaplan-Meier Curve of Patients With >5% Versus <5%
There was a signiﬁcant difference in Kaplan-Meier event rates (p 
those with 5% ischemia improvement. Patients were followed for a mhe addition of 5% ischemia worsening to the
odel resulted in reclassification of 9.3% of the
ample. Of the patients with events, 5.2% correctly
oved up in risk category and 2.3% incorrectly moved
own in risk category when adding 5% ischemia
orsening to the model, resulting in a relative im-
rovement in the event group of 2.9%. For the
ubjects with no events, 6.0% correctly moved down in
isk category and 4.3% incorrectly moved up in risk
ategory when adding 5% ischemia worsening to
he model, resulting in a relative improvement in the
onevent group of 1.7%. Thus, the NRI for the entire
tudy cohort was 4.6% (p  0.0056).
ars
p<0.0001
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721Overall, 129 patients in the cohort were reclas-
sified: 64 to a higher risk category, with a 10-year
event rate of 39.1%, and 65 to a lower risk category,
with a 10-year event rate of 16.9%.
D I S C U S S I O N
To our knowledge, this is the largest reported series
assessing changes in ischemia on serial MPS. We
found that 5% worsening ischemia was a strong,
ndependent predictor of death or MI after adjust-
ent for established predictors and irrespective of
reatment arm. Finally, the addition of 5% wors-
ening ischemia to traditional predictors resulted in
significant improvement in the classification of risk
for prediction of death or MI.
Comparison with the nuclear substudy of COURAGE.
The nuclear substudy of COURAGE examined 314
patients within the overall trial who underwent second
MPS scans (3). Similar to our findings, they showed
hat mean ischemia reduction with PCI (2.7%) was
reater than with MT alone (0.5%). They also found
hat a greater proportion of patients undergoing PCI
ad significant ischemia reduction. The proportion of
T patients achieving 5% ischemia reduction in
COURAGE (19%) was very similar to that in our
study (20%), although ours was an observational
experience. The overall crossover rate from MT to
revascularization was 39.6% in our study, similar to
that in the COURAGE (33%) and BARI-2D (By-
pass Angioplasty Revascularization Investigation 2
Diabetes) (42%) trials (1,2).
In both this study and the COURAGE substudy,
5% ischemia improvement was associated with
decreased risk for death or MI in unadjusted anal-
ysis. In COURAGE, this association was not main-
tained after adjustment to treatment arm, and multi-
variate adjustment to other known predictors was not
possible because of insufficient numbers. Similarly, in
our study,5% ischemia improvement was no longer
significant predictor after adjustment to clinical
ariables. In contrast, we have shown that 5%
schemia worsening is a strong independent predictor,
esulting in significant risk reclassification improve-
ent when added to known predictors. In the
OURAGE substudy, residual ischemia was an un-
djusted predictor of events, but again, this association
as not significant when adjusted for treatment arm,
nd they were unable to perform multivariate adjust-
ent to other known predictors because of insufficient
umbers. Consistent with this, we found that the
ssociation of residual ischemia to events was not
ignificant when adjusted in a multivariate model that
ncluded known predictors and amount of ischemia iorsening. These results highlight the importance of
schemia worsening as a novel independent predictor
f events, perhaps by identifying patients with more
apidly progressive atherosclerotic disease.
Other studies assessing ischemia change during treat-
ment of stable CAD. Several other studies have as-
essed ischemia change during treatment of stable
AD, but none examined its independent prognostic
ignificance. In the INSPIRE (Adenosine Sestamibi
PECT Post-Infarction Evaluation) trial, 205 stable
ost-MI patients with 10% baseline ischemia were
andomized to MT or revascularization (13,14). Isch-
mia reduction was similar with MT and revascular-
zation (15% vs. 16%) and occurred in a similar
ercent of patients (80% vs. 81%). The prognostic
ignificance of ischemia reduction was examined in a
ubgroup of 44 patients in this study and was a
nivariate predictor of major adverse cardiac events
death, MI, and unstable angina). However, the num-
er of patients was insufficient to adjust for other
redictors (15).
Berman et al. (16) reported the change in isch-
mia with MT and revascularization in 421 patients
sing serial MPS scans. In those with moderate
aseline ischemia, they noted similar reductions in
schemia with MT and revascularization (1.8% vs.
.7%). However, in those with severe baseline
schemia, there was significantly greater reduction
n ischemia with revascularization than with MT
13.0% vs. 0.9%). In patients with small baseline
efects, there were no significant changes in isch-
mia seen with either treatment.
In the ACME (Angioplasty Compared to Med-
Table 2. Multivariate Predictors of Death and MI
HR 95% CI C
Age 1.351 1.241–1.470
Noncardiac Charlson index 1.220 1.131–1.315
LVEF 0.930 0.899–0.962
Diabetes 1.511 1.229–1.858
Smoking 1.437 1.188–1.739
Number of diseased vessels 1.234 1.100–1.385
NYHA functional class 1.134 1.055–1.220
5% ischemia increase 1.634 1.198–2.228
White race 0.754 0.616–0.922
History of MI 1.242 1.032–1.496
Hypertension 1.270 1.021–1.580
Treatment with CABG 0.763 0.566–1.027
Amount of residual ischemia on scan 2 0.989 0.976–1.002
Treatment with PCI 0.893 0.728–1.094
CI  conﬁdence interval; HR  hazard ratio; NYHA  New York Heart Associatio
in Table 1.hi-Square p Value
48.4 0.0001
26.5 0.0001
17.7 0.0001
15.3 0.0001
13.9 0.0002
12.8 0.0004
11.5 0.0007
9.6 0.0019
7.5 0.0060
5.2 0.0222
4.6 0.0316
3.2 0.0747
2.6 0.1085
1.2 0.2742
n; other abbreviations ascine) trial, 270 patients with documented 2-
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722vessel disease underwent serial MPS scans before
and after treatment with MT or percutaneous
transluminal coronary angioplasty (17). Although
presence of residual ischemia was found to be a
predictor of survival, neither change in ischemia nor
its prognostic significance was reported.
Implications for imaging in risk assessment of stable
CAD. In current clinical practice, risk assessment of
patients with stable CAD is determined on the
basis of a combination of clinical factors, LVEF,
number of diseased vessels (if known), and amount
of ischemia on objective stress testing. However, it
has previously been shown that the amount of
ischemia is actually a relatively weak predictor of
death and a much better predictor of ischemic
events such as nonfatal MI, unstable angina, and
revascularization (18,19). Nevertheless, amount of
ischemia is 1 of the primary measures driving deci-
sions regarding revascularization. This is based pri-
marily on observational data from 10,000 patients
referred for MPS studies, suggesting that the benefits
of revascularization were confined to patients with
10% ischemia (20,21).
We have shown that worsening ischemia is an
independent predictor of death and MI regardless
Table 3. Ten-Year Risk for Death or Myocardial Infarction as Pr
>5% Ischemia Increase
10-Year Risk in Model Without
>5% Ischemia Increase
10-Yea
<20% >20%–40% >4
20%
Number of patients 130 9
Events 8 1
No events 122 8
20%–40%
Number of patients 14 446
Events 0 91
No events 14 355
40%–60%
Number of patients 0 31
Events 0 7
No events 0 24
60%
Number of patients 0 0
Events 0 0
No events 0 0
Overall
Number of patients 144 486
Events 8 99
No events 136 387
NA  not available.of treatment and other clinical factors, includingLVEF, number of diseased vessels, and residual
ischemia. There was no significant interaction be-
tween baseline ischemia (at scan 1) and worsening
ischemia, indicating that the effect of worsening
ischemia on outcome was not significantly different
in those with greater baseline ischemia. In addition,
the absolute amount of residual ischemia was not a
significant predictor when adjusted to the effects of
ischemia worsening and other clinical factors. This
is not surprising, given that the majority of events in
our population were deaths rather than MIs.
We have shown that there is a significant amount
of risk reclassification when 5% ischemia worsen-
ing is added to risk assessment of patients with
stable CAD. When looking at patients who were
reclassified to higher risk, 39% had events (Table 3).
However, if they were reclassified to lower risk, only
17% had events. This is a 22% relative risk change.
This is a modest change, but that is to be expected
for any individual risk marker, especially in the
presence of all the other established prognostic
variables. To put this into perspective, the magni-
tude of the NRI for 5% ischemia worsening was
4.6% in this study, which compares favorably with
those of other well-established risk predictors, such
ted by Models That Do and Do Not Include
sk in Model With >5% Ischemia Increase
60% >60% Overall
Reclassiﬁed as
Higher Risk
Reclassiﬁed as
Lower Risk
0 0 139
0 0 9 1 NA
0 0 130 8 NA
4 0 484
6 0 97 6 0
8 0 387 18 14
8 31 370
4 18 139 18 7
4 13 231 13 24
0 369 389
4 233 237 NA 4
6 136 152 NA 16
2 400 1382
4 251 482 25 11
8 149 900 39 54edic
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723(4.0%), and parental history of early MI (3.2%) in the
Women’s Health Study (22). However, whether isch-
emia worsening predicts which patients may accrue a
survival benefit with revascularization versus MT is
unclear from this study. This is important to know
before asserting that ischemia worsening should drive
decisions regarding revascularization.
We do not believe that our study can be used as
justification for performing serial MPS scans. Ran-
domized prospective trials are required before any
such recommendations can be proposed. However,
our study provides preliminary data suggesting that
if a patient has had 2 consecutive MPS studies
performed for appropriate clinical reasons, the in-
formation regarding ischemia change may be used
to improve prognostication of these individuals. It is
possible that better risk stratification with serial
imaging may lead to more optimal decisions regard-
ing need for revascularization and subsequent cost
savings in some cases, but this remains unproven.
Study limitations. Because this was an observational
study, there were significant baseline differences
between the treatment groups. Thus, it is difficult to
make definitive conclusions regarding the relative
effectiveness of these treatments. Prospective, ran-
domized studies with similar amounts of baseline
ischemia in all 3 groups are required to address this
issue. However, the differing baseline variables in our
study do not affect our main findings regarding the
predictive power of5% ischemia worsening, because
this was independent of baseline ischemia, as well as
other clinical variables in our multivariate models.
Patients’ treatment was at the discretion of their
cardiologists, and therefore, there may have been
management differences among patients. Our study
encompassed a span of about 16 years, during which
there were changes in MT and treatment goals assive Drug Evaluation (COURAGE) wide beam reconstrPCI. However, neither change in ischemia nor the
proportion of patients with worsening or improving
ischemia was significantly different when compar-
ing subjects in the study from before the year 2000
with those afterward.
Clearly, there was some selection bias in the
patients included in this study, because they were all
seen at a single academic medical center and all
underwent cardiac catheterization. In addition, pa-
tients did not receive second MPS scans routinely
but rather at the discretion of their cardiologists,
thus selecting out a subpopulation that underwent 2
serial MPS scans. However, to some extent, the
patients in this study are more representative of the
population seen in daily clinical practice. They
include those with the full range of CAD severity,
as well as low ejection fractions, prior revasculariza-
tions, and heart failure, which are often excluded
from clinical trials.
C O N C L U S I O N S
In this observational study of patients with stable
CAD undergoing serial MPS scans, 5% LV isch-
mia worsening was a significant independent predic-
or of death and MI. The addition of 5% LV
orsening ischemia to traditional predictors resulted
n significant improvement in the classification of risk.
Our study provides preliminary data suggesting
hat if patients have had 2 consecutive MPS studies
erformed for appropriate clinical reasons, the in-
ormation regarding ischemia change may be used
o improve prognostication in these patients.
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